Clinical trials: Influenza Viral Infections
Influenza, Human, Influenza a
Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
This is a randomized, blinded, active-controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of the Quadrivalent Influenza Virus Split Vaccine (QIV) in subjects (aged 3 years and above).
- Conditions
- Influenza, Human, Influenza a, Influenza Type B, Influenza Viral Infections
- Trial name
- NCT06622590
- Testing
- QIV, QIV control
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
Influenza
Rapid Evaluation of Seasonal Influenza Vaccine
This is an invitation to consider taking part in a research study occurring just before the upcoming influenza vaccination program across Canada.
- Trial name
- NCT00966342
- Testing
- Fluviral 2009/10
- Where
- 3 sites in Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
HIV Infection
Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults
This is a randomized, open label, phase II trial to evaluate the safety and immunogenicity of two different schedules of vaccination against influenza A H1N1 in HIV-infected individuals, in which each of the randomized groups…
- Trial name
- VIP-H1N1 (NCT01155037)
- Testing
- Adjuvanted vaccine against H1N1 influenza virus (GSK)
- Where
- Brazil
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
Autoimmune Diseases
Vaccination Against Influenza in Autoimmune Diseases
The project is to evaluate immunogenicity, efficacy and tolerance of vaccination against influenza (seasonal and H1N1) in patients affected with systemic and autoimmune diseases.
- Trial name
- MAIVAX (NCT01065285)
- Testing
- Evaluation of vaccines against flu
- Where
- France
- Volunteers
- 234 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Otitis, Bronchiolitis
Pediatric and Ambulatory Research in Infectious Diseases
Many ambulatory networks are mainly based on diagnoses made by first-line physicians not specifically trained to join the network.
- Conditions
- Otitis, Bronchiolitis, Influenza, Pharyngitis
- Trial name
- PARI (NCT04471493)
- Where
- France
- Volunteers
- 400,000 people
- Sponsor
- Association Clinique Thérapeutique Infantile du val de Marne
Bird Flu, Avian Influenza
A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine
The focus of this study is to evaluate the safety, reactogenicity and humoral immune responses of the study vaccine when administered at the dose of 7.5 µg HA, 15 µg HA, or 30 µg HA to human subjects.
- Conditions
- Bird Flu, Avian Influenza, Influenza A(H5N1)
- Trial name
- NCT01675284
- Testing
- AT-301
- Where
- Taiwan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Medigen Biotechnology Corporation
Influenza
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
This is a Phase 1, randomized, controlled, dose-ranging clinical trial to assess the safety and immunogenicity of novel influenza A Group 1 and influenza A Group 2 mRNA chimeric hemagglutinin (HA) vaccine candidates given as…
- Trial name
- NCT07703514
- Testing
- cH15/3, cH4/3, cH5/1N1
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (468 subjects): 1st dose : combined vaccination of COVAX+PPV23, 2nd dose: combined vaccination of COVAX+IIV4; Control Group A (468 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia
- Trial name
- NCT05079152
- Testing
- COVAX+PPV23;COVAX+IIV4, COVAX only (1st and 2nd dose), PPV23 for the 1st dose and IIV4 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,404 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Influenza
Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza
This Phase 1/2 protocol is designed to collect safety, tolerability and pharmacokinetic data of two doses of Laninamivir Octanoate in children and adolescents. The protocol will also explore virology and efficacy endpoints.
- Trial name
- FROSTY (NCT02014649)
- Testing
- 20 mg laninamivir octanoate, 40 mg laninamivir octanoate
- Where
- 28 sites in United States
- Volunteers
- 15 people
- Sponsor
- Biota Scientific Management Pty Ltd
Influenza, Orthomyxovirus Infections
Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines
To further characterize the immune responses induced after an influenza vaccination performed either via the ID or the IM routes in two clearly distinct populations.
- Conditions
- Influenza, Orthomyxovirus Infections, Myxovirus Infection
- Trial name
- NCT00776438
- Testing
- Inactivated, split-virion, influenza vaccine, Inactivated, split-virion influenza vaccine
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Anticoagulants, Influenza Vaccines
Influenza Vaccination and Oral Anticoagulant Therapy
The purpose of this study is to evaluate INR and INR related index and Warfarin weekly dosage variations after Influenza Vaccination
- Trial name
- NCT00222638
- Testing
- Influenza vaccination
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University Of Perugia
Viral Respiratory Infection (e.g., Influenza), Bacterial Respiratory Infections
Respiratory Pathogen Distribution During and After the COVID-19 Pandemic
This retrospective observational study aims to evaluate changes in the prevalence and distribution of respiratory pathogens detected by multiplex respiratory polymerase chain reaction (PCR) testing during and after the SARS-CoV-2…
- Trial name
- NCT07601126
- Where
- Turkey (Türkiye)
- Volunteers
- 537 people
- Sponsor
- Hisar Intercontinental Hospital
Cardiovascular Diseases, Influenza
Kaiser Permanente VACCination Improvement With Nudge-based CardiovAscular Targeted Engagement
In randomized clinical trials and observational studies, influenza vaccination is effective in reducing influenza-related illness and hospitalizations and potentially cardiovascular (CV) events and mortality in select…
- Conditions
- Cardiovascular Diseases, Influenza, Behavior, Social
- Trial name
- KP-VACCINATE (NCT06571747)
- Testing
- Cardiovascular-Focused Nudge Communication
- Where
- 2 sites in United States
- Volunteers
- 3,668,428 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Influenza Immunization
Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants
Real-time monitoring of vaccination rates for Germany is unavailable, and up-to-date data publication is delayed, which makes it challenging to develop effective public health strategies to increase vaccination coverage.
- Trial name
- Vakzimeter FLU (NCT06800885)
- Where
- Germany
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Influenza Vaccines
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2584786A in healthy children 6 to 35 months of age.
- Trial name
- NCT01195779
- Testing
- GSK Bio's influenza vaccine GSK2584786A, different formulations, GSK Bio's influenza vaccine GSK2321138A, Fluarix™
- Where
- Spain
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human, Smoking
Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers
Chronic exposure to (cigarette smoke) CS causes biological changes, including airway remodeling and changes in baseline gene expression profiles at the level of the epithelium.
- Conditions
- Influenza, Human, Smoking, Respiratory Tract Infections, Habits
- Trial name
- NCT02019745
- Testing
- LAIV
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
COVID-19, SARS-CoV-2 Virus
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)
The goal of this observational study is to evaluate new non-invasive passive surveillance technologies, Level 42 AI imPulse™ Una and TOR devices for the detection of COVID-19, Flu, and/or RSV in asymptomatic and symptomatic…
- Conditions
- COVID-19, SARS-CoV-2 Virus, COVID-19 Pneumonia, Respiratory Infection
- Trial name
- PassiveDetec (NCT05765396)
- Testing
- imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The Geneva Foundation
Influenza
Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam
The primary objective of this study is to describe the safety of the Quadrivalent Influenza Vaccine (QIV). Safety is assessed throughout the study period, and includes solicited injection site and systemic reactions (Day 0 to Day…
- Trial name
- GQM10 (NCT03765437)
- Testing
- Quadrivalent Influenza Vaccine
- Where
- Vietnam
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
The Impact of Imprinting and Repeated Influenza Vaccination on Adaptive Immunity, Transcriptomics, and Metabolomics
The goal of this study is to understand the impact on the human immune system's response to the four strain flu vaccine in individuals who have "imprinted" on specific influenza strains.
- Trial name
- FLU2 (NCT03686514)
- Testing
- FLUARIX QUADRIVALENT
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Emory University
Respiratory Syncytial Virus
Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age
The purpose of this study is to assess the safety and immunogenicity of RSVpreF when coadministered with SIIV compared to sequential administration of the vaccines when given 1 month apart (SIIV followed by RSVpreF).
- Trial name
- NCT05301322
- Testing
- RSVpreF Vaccine, Seasonal Inactivated Influenza Vaccine
- Where
- 33 sites in Australia
- Volunteers
- 1,471 people, healthy volunteers welcome
- Sponsor
- Pfizer